EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC-ND 4.0

Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4

Yang Zhou, Jingyun Chi, Yuan Ding, Zhidi Zhang, Rui Liang, Tianhao Wang, Yan Jiang, Rujun Song, Huazhou Fu, Xizhen Zhou iD

Phytotherapy Research · 2026-06 · 40 (6) · 3171-3189

DOI: 10.1002/ptr.70308 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2026-03-20. Written by Yang Zhou and 9 co-authors. Institution: Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Pharmacy Department, Suzhou Vocationa…. Major MEDLINE topics: Cyclin-Dependent Kinase 4, Liver Neoplasms, Carcinoma, Hepatocellular, MAP Kinase Signaling System. Cited 1 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The 2024 Jiangsu Association of Traditional Chinese Medicine Eagle Take-off Project, The Medical and Health Technology Project of Hangzhou, The Project of Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Hepatocellular carcinoma (HCC) remains a major challenge in cancer prevention and treatment, highlighting the urgent need for effective and low‐toxicity anti‐HCC therapies. Recently, CDK4‐targeted inhibitors have shown promise in the treatment of HCC. Our study aimed to evaluate the therapeutic potential of pedunculoside (PE), elucidate its mechanism of action in HCC, and explore its potential as a novel natural CDK4 inhibitor in HCC management. We conducted a series of assays, including the cell counting kit‐8 (CCK‐8), colony formation, EdU incorporation, the terminal deoxynucleotidyl transferase (TdT)‐mediated dUTP nick end labeling (TUNEL), and flow cytometry to elucidate the effects of PE on cell viability, proliferation, apoptosis, and the cell cycle. Furthermore, in vivo experiments using xenograft and lung metastasis models, along with acute toxicity assays, were performed to assess the therapeutic efficacy and toxicity of PE. The underlying mechanisms of PE in HCC were explored through a multifaceted approach, encompassing network pharmacology, molecular docking, the cellular thermal shift assay (CETSA), differential scanning fluorimetry (DARTS), and RNA sequencing. The cell viability, proliferation, and apoptosis results indicated that PE effectively suppressed cell proliferation and enhanced apoptosis through mitochondrial pathways in HCC cells. Moreover, PE exhibited a significant in vivo tumor‐suppressive effect, reducing tumor volume, size, and lung metastasis. A network pharmacology analysis suggested that PE targets four key proteins, cyclin B1 (CCNB1), cyclin B2 (CCNB2), cyclin‐dependent kinase 1 (CDK1), and cyclin‐dependent kinase 4 (CDK4), to disrupt the cell cycle. Notably, CDK4 was significantly downregulated by PE treatment both in vitro and in vivo. Cell overexpression and knockdown experiments demonstrated that PE promoted apoptosis and induced cell cycle arrest in the G1/S phase by inhibiting CDK4. Molecular docking, CETSA, and DARTS assays confirmed that CDK4 is a direct target for binding and inhibiting PE. RNA sequencing and a series of in vitro assays, including p38 pathway inhibition, revealed that PE activates the mitogen‐activated protein kinase (MAPK) pathway, exerting a pro‐apoptotic effect by inhibiting and binding to CDK4. Our findings demonstrate that PE directly binds to and inhibits CDK4, thereby inducing cell cycle arrest at the G1/S phase, activating the p38 MAPK pathway, and ultimately promoting cell apoptosis and suppressing HCC progression. These findings highlight the potential of PE as a unique therapeutic agent for HCC treatment.

Subjects

MeSH terms (MEDLINE)

Cyclin-Dependent Kinase 4Liver NeoplasmsCarcinoma, HepatocellularMAP Kinase Signaling SystemHumansAnimalsApoptosisCell ProliferationMiceCell Line, TumorMice, NudeCell SurvivalMice, Inbred BALB CMolecular Docking SimulationMaleXenograft Model Antitumor Assays

Author keywords

MAPK pathwaycell apoptosiscell cycle‐related protein CDK4hepatocellular carcinomapedunculoside

Substances

Cyclin-Dependent Kinase 4CDK4 protein, human

Authors and institutions

  • Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Pharmacy Department, Suzhou Vocational Health College, Suzhou, China.
  • Department of Traditional Chinese Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
  • Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of TCM Pharmacy, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
  • Department of Clinical Pharmacy, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, China.

ORCID profiles: Xizhen Zhou

Funding

  • The 2024 Jiangsu Association of Traditional Chinese Medicine Eagle Take-off Project
  • The Medical and Health Technology Project of Hangzhou
  • The Project of Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology
  • Zhejiang Provincal Traditional Chinese Medicine Science and Technology Plan Project
  • Scientific and Technological Innovation Team Program of Suzhou Vocational Health College
  • The Training Project for Young and Middle-aged Academic Leaders of the "Blue Project" in Jiangsu Universities in 2024
  • The Key Projects of Suzhou Vocational Health College
  • Suzhou Municipal Basic Research (Medical and Health) Scientific and Technological Innovation Project

Cite

APA

Zhou, Y., Chi, J., Ding, Y., Zhang, Z., Liang, R., Wang, T., Jiang, Y., Song, R., Fu, H., & Zhou, X. (2026). Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4. Phytotherapy Research, 40(6), 3171-3189. https://doi.org/10.1002/ptr.70308

Vancouver

Zhou Y, Chi J, Ding Y, Zhang Z, Liang R, Wang T, et al. Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4. Phytotherapy Research. 2026;40(6):3171-3189. doi:10.1002/ptr.70308

BibTeX
@article{Zhou2026,
  author = {Zhou, Yang and Chi, Jingyun and Ding, Yuan and Zhang, Zhidi and Liang, Rui and Wang, Tianhao and Jiang, Yan and Song, Rujun and Fu, Huazhou and Zhou, Xizhen},
  title = {Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3171--3189},
  doi = {10.1002/ptr.70308}
}
Start for free →